Form 8-K - Current report:
SEC Accession No. 0001193125-24-222937
Filing Date
2024-09-20
Accepted
2024-09-20 16:31:04
Documents
14
Period of Report
2024-09-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d881257d8k.htm   iXBRL 8-K 29801
  Complete submission text file 0001193125-24-222937.txt   192794

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA snse-20240917.xsd EX-101.SCH 3872
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE snse-20240917_def.xml EX-101.DEF 14097
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE snse-20240917_lab.xml EX-101.LAB 23426
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE snse-20240917_pre.xml EX-101.PRE 15130
17 EXTRACTED XBRL INSTANCE DOCUMENT d881257d8k_htm.xml XML 5603
Mailing Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850
Business Address 1405 RESEARCH BLVD, SUITE 125 ROCKVILLE MD 20850 (240) 243-8000
Sensei Biotherapeutics, Inc. (Filer) CIK: 0001829802 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39980 | Film No.: 241313780
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)